THERAPEUTIC TRANSPLANTATION USING DEVELOPING, HUMAN OR PORCINE, RENAL OR HEPATIC, GRAFTS

• US 20100221270A1
• Filed: 05/11/2010
• Published: 09/02/2010
• Est. Priority Date: 09/07/2001
• Status: Active Grant

• Current Assignee: Yeda Research and Development Co. Ltd. (Weizmann Institute of Science)
• Original Assignee: Yeda Research and Development Co. Ltd. (Weizmann Institute of Science)
• Inventors: Tchorsh, Dalit, Shezen, Elias, REISNER, Yair, Eventov-Friedman, Smadar, Aronovich, Anna, Katchman, Helena, Dekel, Benjamin
• Granted Patent: US 8,951,572 B2
• Time in Patent Office: Days
• US Class Current: 424/184.100
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 35/22 Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
• CPC Class Codes: A61K 35/407 Liver; Hepatocytes
• CPC Class Codes: A61K 35/54 Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
• CPC Class Codes: A61K 39/39541 against normal tissues, cells
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61L 2430/28 for liver reconstruction
• CPC Class Codes: A61L 27/3604 characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
• CPC Class Codes: A61L 27/3641 characterised by the site of application in the body materials for artificial blood vessels A61L27/507; materials for use in artificial skin A61L27/60
• CPC Class Codes: A61L 27/54 Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Abstract

A method of treating a renal, hepatic or enzyme-deficiency disorder in a subject in need thereof is disclosed. The method is effected by transplanting into the subject tissue derived from a human or porcine, kidney or liver, the kidney or liver being at a selected gestational stage.

Claims

1. A method of alleviating or stabilizing or inhibiting future onset or development of a hepatic or enzyme-deficiency disorder in a subject in need thereof, the method comprising transplanting hepatic organ precursor/tissue into the subject, said hepatic organ precursor/tissue being derived from a human liver being at a stage of development selected from a range of 6 to 14 weeks of gestation, thereby treating the hepatic or enzyme-deficiency disorder in the subject.

2. The method of claim 1, wherein said human liver is at a stage of development selected from a range of 6 to 12 weeks of gestation.

3. The method of claim 1, wherein said human liver is at a stage of development selected from a range of 6 to 10 weeks of gestation.

4. The method of claim 1, wherein said human liver is at a stage of development selected from a range of 6 to 9 weeks of gestation.

5. The method of claim 1, wherein said human liver is at a stage of development selected from a range of 6 to 8 weeks of gestation.

6. The method of claim 1, wherein said human liver is at a stage of development of 7 weeks of gestation.

7. The method of claim 1, further comprising treating the subject with an immunosuppressive regimen prior to, concomitantly with or following said transplanting said hepatic organ precursor/tissue into the subject, thereby promoting engraftment of said tissue in the subject.

8. The method of claim 7, wherein said treating the subject with an immunosuppressive regimen is effected by administering at least one immunosuppressant drug to the subject.

9. The method of claim 8, wherein said at least one immunosuppressant drug is capable of blocking binding of a lymphocyte coreceptor with a ligand of said lymphocyte coreceptor.

10. The method of claim 9, wherein said at least one immunosuppressant drug is capable of blocking binding of a lymphocyte coreceptor with a ligand of said lymphocyte coreceptor, and wherein said administering said at least one immunosuppressant drug to the subject is effected during a time period selected from a range of 1 to 60 days.

11. The method of claim 1, wherein the subject is a mammal.

12. The method of claim 1, wherein said human liver is non-syngeneic with the subject.

13. The method of claim 1, wherein said human liver is allogeneic with the subject.

14. The method of claim 1, wherein the subject is a human subject.

15. A method of alleviating or stabilizing a hepatic or hepatic enzyme-deficiency disorder in a subject in need thereof, the method comprising transplanting a hepatic organ precursor/tissue into the subject, said hepatic organ precursor/tissue being derived from a porcine liver being at a stage of development selected from 27 to 29 days of gestation.

16. The method of claim 15, further comprising treating the subject with an immunosuppressive regimen prior to, concomitantly with or following said transplanting said hepatic organ precursor/tissue into the subject, thereby promoting engraftment of said organ precursor/tissue in the subject.

17. The method of claim 16, wherein said treating the subject with an immunosuppressive regimen is effected by administering at least one immunosuppressant drug to the subject.

18. The method of claim 17, wherein said at least one immunosuppressant drug is capable of blocking binding of a lymphocyte coreceptor with a ligand of said lymphocyte coreceptor.

19. The method of claim 18, wherein said at least one immunosuppressant drug is capable of blocking binding of a lymphocyte coreceptor with a ligand of said lymphocyte coreceptor, and wherein said administering said at least one immunosuppressant drug to the subject is effected during a time period selected from a range of 1 to 60 days.

20. The method of claim 15, wherein the subject is a mammal.

21. The method of claim 15, wherein said porcine liver is non-syngeneic with the subject.

22. The method of claim 15, wherein said porcine liver is xenogeneic with the subject.

23. The method of claim 15, wherein said subject is a human subject.

24. The method of claim 15, wherein said hepatic organ precursor/tissue is a non-cultured hepatic organ precursor/tissue.